342005-82-7
基本信息
物理化学性质
| 储存条件 | -20°C储存 |
| 溶解度 | DMSO: 125 mg/mL (236.02 mM) |
| 形态 | Solid |
| 颜色 | Off-white to light yellow |
NEBENTAN 钾盐价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2026/09/15 | HY-106994A | NEBENTAN 钾盐 Nebentan potassium | 342005-82-7 | 1 mg | 954元 |
| 2026/09/15 | HY-106994A | NEBENTAN 钾盐 Nebentan potassium | 342005-82-7 | 5mg | 2300元 |
| 2026/09/15 | HY-106994A | NEBENTAN 钾盐 Nebentan potassium | 342005-82-7 | 10mM * 1mLin DMSO | 2680元 |
常见问题列表
|
ET A 0.679 nM (Ki) |
ET B 569 nM (Ki) |
Nebentan potassium inhibits the specific binding of [ 125 I] endothelin-1 to endothelin ET A and ET B receptors in a concentration dependent manner, K i values are 0.697 nM and 1.53 nM for human and rat endothelin ETA receptors, respectively. In contrast, YM598 exhibits low affinities for human and rat endothelin ET B receptors, with K i values of 569 nM and 155 nM,respectively.In measurement of intracellular Ca 2+ concentration, Nebentan potassium concentration-dependently inhibits the increase in [Ca 2+ ]i induced by 10 nM endothelin-1 in both CHO cells and A10 cells, the IC 50 values are 26.2 nM for CHO cells and 26.7 nM for A10 cells, respectively.
Nebentan potassium (oral administration; 0.1-1 mg/kg; 4 weeks) significantly inhibits the progression of pulmonary hypertension and the development of right ventricular hypertrophy.Nebentan potassium (oral administration; 1 mg/kg; 30 weeks) significantly ameliorates the poor survival rate of CHF rats, it markedly reduces the hypertrophy of both ventricles as well as pulmonary congestion.